UNLIMITED TURBO SHORT - GILEAD SCIENCES | Delayed Deutsche Boerse AG 19:50:24 11/06/2024 BST | ||
| 4.47 EUR | +1.13% |
|
| Current month | -1.12% | ||
| 1 month | +1.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 11/06/24 | 4.47 | +1.13% |
| 10/06/24 | 4.42 | -0.45% |
| 07/06/24 | 4.44 | -1.11% |
| 06/06/24 | 4.49 | +0.45% |
| 05/06/24 | 4.47 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 11, 2024 at 07:50 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE5169 |
| ISIN | DE000PE51695 |
| Date issued | 28/11/2022 |
| Strike | 112.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.96 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.67 € |
|---|---|
| Lowest since issue | 2.32 € |
| Spread | 0.01 € |
| Spread % | 0.22% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.25
USD
Average target price
82.7
USD
Spread / Average Target
+26.74%
- Stock Market
- Certificates
- Certificat